July 22, 2026

Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma

Preclinical research showed antiproliferative activity against NRAS-mutant melanoma cell lines and antitumor activity against preclinical melanoma models.

The ASCO Post

July 22, 2026

Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma

Preclinical research showed antiproliferative activity against NRAS-mutant melanoma cell lines and antitumor activity against preclinical melanoma models.

The ASCO Post

July 09, 2026

Targeting BCL2 May Overcome Acquired Resistance in BRAF-Mutant Melanoma

Targeting BCL2 family proteins may counteract acquired resistance to BRAF and MEK inhibition in patients with BRAF-mutant metastatic melanoma, according to findings from a preclinical study published ...

The ASCO Post

July 09, 2026

Targeting BCL2 May Overcome Acquired Resistance in BRAF-Mutant Melanoma

Targeting BCL2 family proteins may counteract acquired resistance to BRAF and MEK inhibition in patients with BRAF-mutant metastatic melanoma, according to findings from a preclinical study published ...

The ASCO Post

July 06, 2026

Preclinical Research Shows IFN-γ May Attenuate Neutrophil Response to Cancer Immunotherapy

Researchers have discovered that the type II interferon, interferon-γ, may impact how neutrophils react to immunotherapy, either supporting or blocking the treatment for patients with cancer, accordin...

The ASCO Post

July 06, 2026

Preclinical Research Shows IFN-γ May Attenuate Neutrophil Response to Cancer Immunotherapy

Researchers have discovered that the type II interferon, interferon-γ, may impact how neutrophils react to immunotherapy, either supporting or blocking the treatment for patients with cancer, accordin...

The ASCO Post

June 24, 2026

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

UCI Health

June 03, 2026

Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma

The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared wit...

The ASCO Post

June 03, 2026

Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma

The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared wit...

The ASCO Post

May 08, 2026

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

A cohort study showed that patients with melanoma who received BRAF or MEK inhibitor therapy commonly experienced hypertension and mild cardiac dysfunction, supporting baseline cardiotoxicity risk str...

The ASCO Post